Biogen Inc. (BIIB) Earnings Call Transcript & Summary
November 8, 2023
Earnings Call Speaker Segments
Chuck Triano
executiveThanks, Allie. Hello everyone, and good morning — glad to have you on Biogen's Q3 2023 earnings call. First, a quick reminder: you can find the earnings release along with the related financial tables in the Investors section of biogen.com — those tables include our GAAP measures and a reconciliation between GAAP and the non-GAAP measures we'll be discussing today. Our GAAP figures are shown in tables 1 and 2, while table 4 provides a reconciliation of GAAP to non-GAAP results. In our view, non-GAAP results give a clearer picture of the business's ongoing economics and mirror the way we run things internally; we've also put slides on our website that accompany the discussion for this call. Before we begin, please note that today's remarks will include forward-looking statements reflecting our current expectations. Such statements carry specific risks and uncertainties, meaning actual outcomes could differ substantially. For further information, I suggest reviewing the risk factors outlined in our SEC filings. Joining me on the call today are our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; and our CFO, Mike McDonnell. Each of them will offer opening remarks, after which we'll open the floor for Q&A. So that we can address as many questions as possible, we kindly ask each of you to limit yourself to one question. Chris, over to you now.
Christopher Viehbacher
executiveThank you so much, Chuck. Morning, everyone. I believe we put out a strong set of results this morning that came in above expectations. Yet naturally, all of us are keenly aware that what the majority of you care about most is this: where is Biogen headed? With that in mind, we laid out 5 priorities we felt had to be delivered to get Biogen into a position where it could return to sustainable growth. And I'd say across the first 9 months of this year, we have made a great deal of progress, and in fact, the third quarter stood out as an especially busy one. As a reminder of those priorities: the first was concentrating our teams and resources on launching new products. That sounds simpler than it is. We are a company with a long history in treating multiple sclerosis, and teams grow deeply committed to patient outcomes and to their work with physicians, so shifting them into new areas genuinely takes a concerted effort. Another goal is to steady and then regrow the existing products that retain market exclusivity for a meaningful stretch of time, most notably VUMERITY and SPINRAZA. Number three involved taking a hard look at our cost base. Even though our product portfolio was fairly mature, our OpEx to sales ratio ranked among the higher ones in our peer group, and that had to be tackled — and beyond that, we truly needed to reallocate resources. Fourth, we set out to examine our research and development pipeline closely, especially with an eye on the longer-term growth outlook. We went deep into R&D, reviewed the products and projects that maybe no longer met their original target product profile, where medical practice had shifted, where the probability of success had shifted, and we ended those programs so we could concentrate on the assets we view as most promising. I think we hold a number of those, and any single one could genuinely contribute meaningfully to growth over the longer term. And finally, we stated from the very beginning that external growth interested us. We understood all along that the LEQEMBI launch would be a gradual one. We also understood all along that even the zuranolone launch was unconventional, and in order to de-risk that profile, we wanted to pursue external growth, and naturally, we've managed to do so. So when I consider where things stand in the third quarter, Leqembi actually became the first anti-amyloid antibody to win traditional approval for early Alzheimer's disease. Zurzuvae was a mixed bag. We achieved a key approval in postpartum depression, even though we did not succeed in major depressive disorder. The DEA granted us Schedule IV status, as we had anticipated. We also saw Qalsody cleared for a genetic form of ALS. Revenue-wise, this may not be a product that appeals to many of you, but scientifically it represents a significant milestone, and I think that confirming the neurofilament biomarker will enable numerous researchers to find further ALS therapies and potentially treatments for other conditions. As I noted, we finished the Reata Pharmaceuticals acquisition, which gives us a completely new avenue for growth. Skyclarys has gotten off to a really impressive start, and we'll get into that in a moment. Beyond that, it broadens our rare disease portfolio. As you're aware, we're working to expand into some adjacent areas, since the neurological conditions we've historically concentrated on carry risk, and rare diseases has been a natural direction for us. Biogen has enjoyed considerable success with the Spinraza launch, and we think we can do the same with Skyclarys. As I mentioned before, we had the Fit for Growth program, and it wasn't just about cutting costs, since we do want to reinvest some of that, but we really needed to simplify the organizational structure, to empower the organization more and shift more decision-making closer to markets and customers. We ended up removing an entire layer enterprise-wide from the organization, and in some parts of the organization, even two layers. So we do believe those cost savings will contribute meaningfully to our earnings per share going forward. But I'm also looking forward to a significant cultural change in how we allocate capital and the agility and the ability to make decisions in the organization. May we advance to the following slide? Now I'd like to discuss LEQEMBI, which I'm certain is a topic of great interest to everyone here. Our guidance has consistently been that this launch would unfold gradually. That view stems in part from what we learned with Aduhelm, and in part from the basic nature of what we're undertaking; this product must be given as part of a treatment process or care network, and no such care networks were in place when we launched, meaning they must be constructed. Accomplishing that calls for a fairly substantial shift in how clinics organize their workflow. IDNs and clinics are putting in real effort to get these programs up and running, though naturally that doesn't happen overnight. The recent announcement from the Cleveland Clinic strikes me as a great illustration. As everyone knows, the Cleveland Clinic ranks among the most respected medical centers in the world, and they shared that they had only just given their first Leqembi infusion to a patient — months after the approval. To me, that really highlights how complex this situation is. In many respects, we're not just breaking new ground scientifically; we're also breaking new ground on the commercial side. Of course, our aim is to get to 10,000 patients by the end of March. Right now we're sitting at 800. So what makes us believe we can get there? Well, I'd point to several green shoots, some encouraging signs. First, when we examine our internal metrics around intent to treat and patient demand, all of those are moving along very well indeed. The FDA didn't just grant traditional approval — CMS acted quite swiftly as well. On the very day of traditional approval, just as they'd pledged, reimbursement was in place, and based on what we're hearing from the market, the patient registry has proven fairly straightforward to use so far. There was a bit of confusion regarding amyloid PET reimbursement, and CMS has since cleared that up. Naturally, some lag will occur before that reaches the MACs, yet in my view it should reduce a portion of the current bewilderment. A particularly notable item, I would argue, is that P&T approval is now held by 60% of the top 100 targeted IDNs.
Christopher Viehbacher
executiveAnd, you know, something that truly inspires me a great deal is that these P&T committees typically convene twice annually, yet quite a few of them have actually set up dedicated sessions specifically for LEQEMBI rather than waiting for the next scheduled meeting. To me, that signals an acknowledgment of how important this therapy is and of the ability to get patients started on treatment; so where do we go from here as well? Remember that twelve months ago, there was still doubt about whether reducing amyloid plaque would actually produce any real benefit. It wasn't until the Clarity study was finally shown at CTAD last year that we had, for the first time, unambiguous and convincing proof that clearing those plaques helps. And today, naturally, we can say: fine, that's amazing — but what makes it so amazing? For many years we kept trying to create antibodies, and those attempts did not succeed. That is exactly what fueled the doubt. Which patients were the correct ones? Which antibody would deliver the proper quantity of drug into the brain? LEQEMBI is truly the first to demonstrate clear, compelling evidence that this has happened; naturally, we all now want to get fancy, and that is where we are headed. We just had CTAD this year, and consider what we have just accomplished. We are producing additional data to genuinely show the benefit of this treatment. For instance, we have observed that subcutaneous treatment is going to work, and that we have comparability with the infusion. This matters enormously for patient convenience; but this is no small feat either. Others have attempted this, you know. How can you get sufficient drug through muscle tissue and into the brain? That has been accomplished, and it's a major milestone; we've been examining maintenance dosing. What happens once the plaque has been cleared? Does it return? Well, we now have 24-month data demonstrating considerable benefit from remaining on treatment. Then the question remains: who is the right patient? And data were presented involving early-stage patients with low tau levels, and those data are fascinating. You know, 76% of those patients stayed stable throughout the measurement period. And it was quite compelling and quite fascinating—with 60% of those patients, we in fact observed some clinical benefit as measured by the CDR sum of boxes. Entirely unexpected. That sparked a great deal of discussion at CTAD. So at this point, of course, we are likewise focused on carrying out geographic expansion. We had the recent approval in Japan, and I will be traveling to Japan early in the new year to join my friend and colleague, the CEO of Eisai, to launch Leqembi in Japan. And of course, we currently have global filings under review in the EU, China, and 10 additional markets. This is a case where we'll need to be patient, but at the moment everything appears to be moving in a positive direction. From where we sit internally, the launch is still on schedule; however, as we've said all along, there really aren't any true comparables, and every month teaches us something new. Chuck, if we could move to the next slide, let's turn to Skyclarys. This one is, as you know, fairly different. As you're aware, we have 1,180 start forms so far, and about 860 patients are actually on the drug. Looking at every comparable launch we know of, we are in fact outperforming each one—Spinraza included—at the same stage; that said, some caution is warranted, since we all know physicians probably had a group of patients lined up and waiting. And I think that dynamic was even stronger because, as you may recall, the product won approval in the spring but then slipped by a couple of months owing to a temporary technical issue with supply. So I think people were anticipating it. Even so, there's a really strong wish for this product to become available, and in fact we're getting many inquiries from nations worldwide asking us to supply Skyclarys. That reflects, I believe, the recognition that this is the first-ever therapy ever approved for Friedreich's ataxia. It's a profoundly debilitating condition that strikes so many young individuals right in their prime. So it matters enormously that they get the benefit of it. Third-quarter sales came to roughly $43 million. One area we're focused on right now—and I believe this is a place where Biogen can genuinely contribute—is understanding the gap between the $1,180 shown on start forms and the $860 for the drug. Several factors are involved: securing reimbursement, the need for genetic testing, and checking liver enzymes prior to starting the product. And unlike Spinraza, not all of these are incentives. These patients could be in primary care or physician care settings; but Biogen is well prepared for that, and providing genetic tests is something we're accustomed to doing. Reimbursement isn't something we stress over — we handle that. Our mobile labs let us reach patients far from major medical centers, so they can get things like lab enzymes done. Beyond that, we're experienced at pushing through those start forms and steering our way around a tough reimbursement landscape. So I'd say Biogen benefits not just by delivering this important medicine to patients worldwide, but here in the United States as well, we can genuinely get it to patients faster. That said, Priya, the floor is yours.
Priya Singhal
executiveThanks, Chris. It was a thrilling quarter for Biogen's development team: Zurzuvae won approval for postpartum depression, and we shared significant new data on Leqembi as well as our tau-targeting ASO, BIIB080. We see these two programs as essential for extending Biogen's lead in Alzheimer's disease. Starting with Leqembi: at CTAD last month, Eisai shared new findings on a subcutaneous version of Leqembi. From our perspective, the six-month interim results indicated that subcutaneous Leqembi matched the IV formulation when it came to drug exposure—measured through area under the curve—and also in amyloid plaque clearance. On safety, we think the timing, frequency, and severity of ARIA-E came out similar for both the IV and subcutaneous versions. Beyond that, the overall rate of systemic reactions for subcutaneous LEQEMBI was lower as well, with mild symptoms, when set against patients receiving LEQEMBI IV for the first time in the Clarity AD core study. In our view, these findings reinforce the rationale for creating a subcutaneous version of LEQEMBI, and should it gain approval, that could broaden access for patients while also improving adherence and making things more convenient. Our grasp of the possible clinical advantages tied to clearing amyloid in Alzheimer's disease has advanced considerably. Even so, plenty of important unresolved issues remain regarding how best to obtain the fullest clinical benefit from such therapies, one of which is the timing of when treatment should start. We believe the distinctive, uncomplicated structure of the Clarity AD trial—permitting enrollment of Alzheimer's patients who have confirmed amyloid pathology yet a low tau burden—lets us derive further understanding of LEQEMBI's clinical profile throughout different stages of Alzheimer's disease... The data indicate that among the low tau subpopulation—which reflects the earliest phases of early AD—76% of patients exhibited no decline, and 60% demonstrated clinical improvement at 18 months according to CDR sum of boxes, versus 55% and 28% for placebo, respectively. These findings give us a great deal of encouragement. Another central question the field faces is what occurs if treatment is continued once amyloid plaques have been cleared, and what the rationale would be for that benefit. Our view is that LEQEMBI, with its dual mechanism, keeps supporting brain neuron function by additionally clearing soluble, highly toxic protofibrils capable of causing neuronal injury and death even after plaques are gone. So with LEQEMBI, we think there's a possibility that treating patients over a longer period could preserve or even build on the clinical gains seen during the initial phase when plaque is being cleared. As for the evidence behind that possibility, looking at the 24-month data from the Clarity AD core study along with the open-label extension, we observe a possible clinical advantage from keeping patients on LEQEMBI. To be specific, the gap in CDR sum of boxes separating those who stayed on LEQEMBI — the early start group — from those who moved from placebo over to LEQEMBI — the delayed start group — held steady through the 6-month open-label extension that followed the core study, which points toward a disease-modifying effect. What we saw at 24 months in the early start group—that clinical benefit—gains additional support from a comparison with ADNI observational natural history cohort participants, chosen so their baseline demographics and clinical characteristics matched those of the Clarity AD population. And although the delayed start Leqembi cohort doesn't catch up with the early start group, we do think there may be a potential slowing of decline following six months of Leqembi treatment relative to the ADNI cohort at the 24-month time point; in our view, the totality of these data backs both how important it is to begin treatment early and the durability of effect seen with continued Leqembi treatment. Eisai is currently looking at maintenance dosing—giving Leqembi every four weeks once plaques have been cleared—with the aim of providing patients with options, and intends to file with regulators before the end of Q1 2024. Biogen also shared fresh findings at CTAD from the phase Ib trial of our antisense oligonucleotide aimed at tau. In these latest results from that small study, patients who received the two highest doses of BIIB080 showed encouraging trends on several exploratory measures of cognition and function—the CDR-SB, MMSE, and functional activities questionnaire—compared with baseline-matched external controls at week 100. Those results extend earlier observations from the phase Ib study of BIIB080, where researchers saw robust target engagement in cerebrospinal fluid along with less tau pathology in the brain, as assessed through tau PET. Data on biomarkers covering the placebo-controlled portion and the long-term extension of that trial appeared recently in JAMA Neurology. Alzheimer's drug development has for years concentrated on tau, which is regarded as a fundamental pathology of the disease. Although numerous earlier efforts with monoclonal antibodies didn't succeed, the phase Ib trial of an antisense oligonucleotide aimed at tau now shows evidence coming together from soluble biomarkers, tau PET, and exploratory clinical measures—pointing to a connection between less tau pathology and possible clinical benefit. To recall, our tau-targeting ASO works through an entirely novel mechanism; in contrast to the antibodies, it's built to cut down production of every tau form, covering both intracellular and extracellular species. A notable difficulty we observed with antibodies was that they couldn't reach intracellular species. These findings are early, but we find them encouraging, and we're eager to be enrolling patients in the phase II CELIA study of BIIB080 for early AD. In recent months, I've discussed how we're reprioritizing Biogen's development pipeline to optimize R&D value and productivity. That gave us a chance to review our pipeline with fresh eyes and pinpoint areas where we have adequate expertise and scientific confidence, along with the capability to deliver meaningful new treatments to patients, while directing resources accordingly... We'll start with Alzheimer's, a field where we believe we've demonstrated scientific leadership and where we're now acting to create lasting impact. That means, first, collaborating with Eisai on multiple efforts designed to set Leqembi apart and give patients more options. Second, we're pushing forward with our tau-targeting ASO, along with preclinical programs covering a range of molecular targets and approaches within Alzheimer's disease biology. And finally, we keep generating fresh understanding of Alzheimer's disease biology and of long-term therapy using anti-amyloid antibodies. On that last point, at CTAD we also shared new aducanumab data, among it new results from the EMERGE long-term extension and the EMBARK redosing study; in our view, these findings can aid the field in grasping the possible long-term treatment benefits tied to anti-amyloid antibodies. Beyond Alzheimer's, we see quite a few near-term catalysts coming up over the next year, spanning several programs and therapeutic areas. Among them are regulatory rulings for LEQEMBI across various geographies, as well as regulatory rulings for other products; on top of that, we're expecting key data readouts for BIIB105 in ALS, BIIB121 in Angelman syndrome, and dapirolizumab pegol in SLE, all anticipated around midyear 2024. Add to that the longer-term potential of programs like litifilimab — our own asset, which is currently being studied in two phase III trials for SLE and a phase II-III trial for CLE — and we believe the pipeline can help bring Biogen back to sustainable growth. Meanwhile, working with our partners on the research and business development teams, we've continued to evaluate outside opportunities. I'll now hand the call to Mike.
Mike McDonnell
executiveAppreciate that, Priya, and hello everyone. I'll cover a few key points and give you more detail on our financial results for Q3 2023, and all comparisons I mention are versus Q3 2022. Total revenue for the quarter was $2.5 billion, up 1% in actual currency and 3% on a constant-currency basis. Non-GAAP diluted EPS in Q3 was $4.36. Revenue from all MS products totaled $1.2 billion, a decline of 14% at actual currency and 12% at constant currency. The drop is primarily due to generic competition for Tecfidera as well as widespread competition throughout the MS category. I want to provide a few MS business updates from the quarter. First, in Europe, we keep seeing that certain generics have not yet completely exited some EU markets, and we do believe some generic product may still be sitting in the channel. Generic withdrawal has moved more slowly than we anticipated, but we are monitoring the situation closely and working to enforce our legal rights to market protection. A TYSABRI biosimilar received approval in both the U.S. and EU, which we had previously assumed would happen. At this point, we aren't expecting a launch this year, though we are aware of plans to launch a biosimilar in the first half of 2024. Biogen continues to hold patents relating to TYSABRI, and we will keep enforcing our IP. VUMERITY was a clear standout during Q3. Its revenue climbed 20%, primarily on the strength of patient gains worldwide. Even so, pricing pressure persists, and the U.S. oral segment keeps shrinking overall. Moving on to Spinraza, worldwide revenue reached $448 million, up 4% as reported and 7% in constant currency terms. That 7% increase also reflected 7% growth within the US, fueled by more patients, and beyond the US, shipment timing in select markets gave Spinraza a lift. We're still feeling positive about Spinraza's results across the last several quarters, and we keep believing that solid headway is being made toward our objective of getting Spinraza back to steady growth over the longer term. Turning to biosimilars, revenue for the third quarter came in at $194 million, which was up 4% at actual currency and 7% at constant currency. In the third quarter, we altered the way we present commercialization expenses incurred within the LEQEMBI collaboration. Our 50% share of LEQEMBI net product revenue and cost of sales, royalties included, will still be classified as a component of revenue. For the LEQEMBI collaboration, the 50% portion Biogen bears of worldwide commercialization, sales, and marketing costs is now reported within SG&A rather than being shown as a subtraction from revenue. During Q3 2023, roughly $39 million in commercial collaboration costs from the first two quarters of 2023 were reclassified to align with this change. That amount shifted out of the revenue line and into SG&A, lifting both revenue and SG&A by $39 million in the third quarter while leaving the bottom line unchanged. None of our agreements with Eisai are affected by this reporting change, and we continue to split LEQEMBI collaboration revenue and commercialization expenses 50/50. This adjustment gives us clearer reporting and matches the approach a number of other companies in our sector take when disclosing collaborations; it won't affect Biogen's bottom line at all. Per Eisai's report, LEQEMBI's in-market product revenue for Q3 was about $2 million. Revenue from our anti-CD20 franchise reached $421 million, a total that encompassed an $11 million operating loss tied to Lunsumio. Contract manufacturing, royalty, and other revenue came in at $304 million, markedly above the prior year, chiefly because of batch timing, and it also contains the $39 million reclassification I referenced earlier. There are a few items worth flagging about third quarter expenses. For the third quarter, non-GAAP cost of sales came in at 26% of total revenue, a figure that includes $35 million in idle capacity charges. Product mix continues to affect cost of sales as a share of revenue, and this quarter that impact was driven especially by growth in contract manufacturing revenue. Within third quarter non-GAAP R&D expense, roughly $44 million relates to our portion of the Leqembi collaboration, alongside about $37 million of closeout costs tied to the EMBARK trial for Aduhelm. Third quarter non-GAAP SG&A expense reflects approximately $82 million connected to our share of the Leqembi collaboration, which includes the $39 million reclassification of collaboration costs mentioned earlier — moved out of revenue and into SG&A expense — covering the first and second quarters of 2023. Looking at the third quarter, non-GAAP SG&A expense came in lower than a year earlier. About $100 million of that drop came from our cost savings initiative, though it was partly offset by higher commercialization spending on Leqembi and Zurzuvae, plus the $39 million reclassification I mentioned a moment ago. Now a few quick notes on the balance sheet. We closed the quarter with $2.3 billion in cash and marketable securities against $7.3 billion of debt, which leaves us in a net debt position of roughly $5 billion. Although most of the payments tied to closing the Reata deal are reflected in these numbers, keep in mind that we anticipate spending roughly another $1.3 billion in cash to cover remaining obligations from that transaction, and that should happen during Q4. We're still producing consistent positive operating cash flow, with $518 million of free cash flow generated in the third quarter. In the coming quarters, some of that cash flow will go toward paying down a share of the approximately $1 billion of short-term debt we incurred to help finance the Reata acquisition. Moving on, I want to walk through an update on our full-year 2023 financial guidance, which reflects three significant recent developments. The first is the closing of the Reata acquisition; the second is the regulatory green light for Zurzuvae in postpartum depression; and the third is the change we made in how we present Leqembi expenses. We are now revising our full-year 2023 revenue guidance to a low single-digit % decline, an improvement over the prior guidance of a mid-single-digit % decline — naturally, both measured against full-year 2022 reported results. The main driver here is the update to our presentation of Leqembi commercial expenses, which are no longer shown as a reduction to revenue. We're also updating and narrowing the guidance we gave for full-year 2023 non-GAAP diluted earnings per share, which now sits in a range of $14.50 to $15. As we mentioned previously, the Reata acquisition will be modestly dilutive to our 2023 non-GAAP EPS, and we expect an impact of approximately $0.75. Much of that effect comes from how we financed the deal, which pressures our operating income and expense line—including greater interest expense as well as a sizable decline in interest income.
Mike McDonnell
executiveIf we set aside the effect of the Reata transaction, our EPS guidance would be tightened to $15.25-$15.75, which aligns with the midpoint of the guidance we gave previously. In addition, for 2023 we anticipate certain incremental OpEx tied to the Reata acquisition, and that will be mostly offset by lower spending on ZURZUVAE as we get ready to launch in the PPD indication. We also anticipate certain savings in 2023 from our Fit for Growth program. As we look ahead to 2024, it is very important to note that because of the Reata transaction, we will hold roughly $6 billion less in cash that had been earning interest income at about 5%, plus an additional $1 billion of debt at a blended rate of roughly 6.7%. I would also note that across the full year of 2023, we absorbed a headwind of roughly $0.30 to EPS from currency fluctuations, and this is a dynamic we are monitoring very closely for 2024. I would offer that we estimate each $0.01 move in the euro against the US dollar has an impact of roughly $18 million to our P&L. I would also point you to our press release for other important guidance assumptions. Lastly, a brief update on our Fit for Growth cost savings initiative. I would begin by reiterating that the program keeps its target of roughly $1 billion in gross savings by 2025, compared with full year 2023. Since we first announced the program, we have made no changes to our planned level of reinvestment, apart from the acquisition of Reata and the regulatory approval for ZURZUVAE and PPD only, neither of which were part of our original assumption. The expected impact of Reata and ZURZUVAE on the original program is roughly a net decrease in expected reinvestment of $100 million. Or put differently, we now expect an additional $100 million in net savings, so the original $700 million in expected net savings rises to roughly $800 million. I would also just highlight that these figures do not include the impact of the Leqembi commercial spend, which will now be reflected in our SG&A line and will, of course, continue to ramp up as commercial activity and sales increase; and I would also like to point out that, as before, the expense estimates presented today did not contemplate any incremental business development or any transactions related to the biosimilars business, and they assume continued R&D spend on Aduhelm through at least 2025. I will now turn the call back to Chris for some closing remarks.
Christopher Viehbacher
executiveThanks, Mike. So 2024 is already part of our AOP planning process; and looking ahead to next year, we genuinely have several milestones lined up, which is encouraging to see. As I noted before, an EMA decision is coming on Leqembi in the EU, and in China, there will be a decision on Skyclarys in the EU and Qalsody in the EU, all during the first half of next year. Two further significant regulatory submissions are planned — one covering the subQ formulation and one for the IV maintenance dosing, both for Leqembi; and then lastly, we are beginning to see development readouts emerge from the pipeline. Dapirolizumab pegol, a phase III trial in SLE, is expected in the new year. Our ASO for sporadic ALS will read out on a phase I/2, a phase I in Angelman syndrome, and naturally, with Sage, the SAGE-324 program in essential tremor; so, I believe there will be quite a few interesting news points for next year. With that, Chuck, I think we can open it up for questions.
Chuck Triano
executiveThank you, Chris. Allie, can we please poll for questions? Thank you.
Salveen Richter
analystMorning, and thanks for taking my question. On the Reata assets — the deal's now closed and the launch is going well, so I'd like to hear how you see the main near-term value drivers: how the launch is tracking, what you expect from the EMA on approval early next year, and then the pediatric expansion. Thank you.
Christopher Viehbacher
executiveRight; SPINRAZA is actually a good analog here. One nice thing about rare disease, you know, is that we tend not to be so U.S.-centric. When you look at how SPINRAZA's revenue breaks down, it's approximately — though not precisely — split in equal thirds across the U.S., the EU, and the rest of the international market. And really, we anticipate the same pattern for SKYCLARYS. So we do expect meaningful value to emerge from the EU as well as Latin America, and possibly some from the Middle East and Turkey. For genetic reasons, of course, there's nothing in the Asia region. But we're aware that there are a good number of patients, in Brazil and Argentina for example. So we're stepping up our efforts to submit for approval in Latin America. Regarding the EU, well, you never want to attempt to fully predict what regulators will do. Their call-making authority through to the finish deserves respect. Still, nothing observed to this point meaningfully shifts how we assess the odds of EU approval. That representative — as you may recall, when the deal was struck we put it at roughly one-third of the transaction's worth. As for the pediatric study, talks with regulators are ongoing. This matters a great deal, since quite a few patients begin receiving a diagnosis at ages as young as five or six, and definitely within the eight-to-ten-year-old range; therefore getting the pediatric study started is essential.
Chuck Triano
executiveThank you, Chris. Can we move to our next question, please?
Chuck Triano
executiveBrian, I can't hear you.
Geoff Meacham
analystHi, everyone. Morning, and thanks for asking. I just had a question about Leqembi maintenance. As we consider the strategy, I suppose what I want to know is: do you have any regulatory insight regarding a distinct maintenance claim, particularly given the initial focus on plaque reduction? And then, tied to that, would an extra level of evidence be required? Thinking about maintenance with regard to CMS reimbursement. Thank you.
Chuck Triano
executiveI'll pass that one, Geoff, to Priya.
Priya Singhal
executiveThanks, Geoff. On the maintenance question, what I can say is that Eisai has told us—as you're aware—that testing is happening at 4-week intervals. That applies to the intravenous infusion, and the expectation is for this data to be filed by Q1 2024. As for what indication and so forth that might lead to, I'm not in a position to comment, but we're getting the data ready for a possible filing.
Chuck Triano
executiveThank you, Priya. Operator, could we take the next question?
Brian Abrahams
analystHello, good morning. Are you able to hear me at this point?
Chuck Triano
executiveYes, Brian, we can. That's right.
Brian Abrahams
analystAlright, apologies. I'm not sure what went on just before that. So, yes, thank you for the question. Congratulations on everything that's been accomplished. So, following CTAD regarding SubQ Leqembi, I understand there are still FDA discussions that need to happen. Could you, but could you perhaps help us get a handle on your most recent view of what will likely be needed for approval? How much additional patient data, if any, do you believe you may need to produce for a dose you might move ahead with? Would you expect to be able to file for a lower dose on the basis of PK modeling? And perhaps you could verify whether the additional patients still coming through the trials there are still showing exposure under the 100, 125% upper bound. Thank you.
Chuck Triano
executivePriya, did you catch all of that?
Priya Singhal
executiveYes. Thanks, Brian. So we're genuinely encouraged by the subcutaneous interim data we shared, and that Eisai shared at CTAD. To take a step back, the subcutaneous study was a sub-study within the open-label extension for Clarity AD. The treatment-naive patient population, where we were really assessing the PK/PD — meaning the PK parameters — along with the PD outcome of amyloid plaque reduction, was a subset of 72 patients. Beyond that, the study was designed to collect safety and tolerability in an additional 200 to 324 subjects. That makes the total study population 394, and what we shared was our belief that the subcutaneous formulation demonstrated comparability and bioequivalence with the intravenous formulation. It fell within the confidence intervals of 80% and 120% — and 125% — of exposure. We also noted that overall area under the curve was roughly 11% higher with subcutaneous, and we further noted a 14% increase in plaque reduction at the 66-month time point. So those are the kinds of observations we have from the data. We've had prior regulatory discussions, and we're now embarking on additional meetings with the FDA to share the data with them and talk through next steps. So that's where we stand at this point. The plan, as Eisai has communicated, is to file for a BLA in Q1 2024, and that's really the update. Eisai has also commented potentially on a maintenance subcutaneous formulation and filing, but that comes much later, in the 2025 timeframe; so that's where we are right now. I hope I answered all your questions. Happy to follow up, if not.
Chuck Triano
executiveThanks, Priya. Let's go to our next question, please.
Chuck Triano
executivePlease go ahead.
Robyn Karnauskas
analystHello, and thanks for taking my question. I'd just like to understand how you're thinking about how long treatment lasts, in light of your maintenance data. With what you currently know about LEQEMBI, how should we think about modeling how long patients might remain on the drug? Thank you.
Chuck Triano
executivePriya, why don't you begin with that, and then perhaps I can wrap up from a commercial perspective.
Priya Singhal
executiveYes. Thanks, Robin. So if we take a step back and consider how Alzheimer's disease progresses, we know patients do actually experience plaque reduction, but we now have data from multiple sources — LEQEMBI, Aduhelm, and others — showing that although plaque slowly builds back up at roughly 3%-4% per year according to current understanding, the biomarkers that truly reflect disease progression keep accumulating the moment patients stop taking the drug, at least with LEQEMBI and Aduhelm; and this rests on the Aβ 42/40 ratio, as well as other pathological biomarkers. We've also demonstrated, most recently at CTAD, that in fact keeping patients on treatment for the 24-month period — and we presented data on that, which I also covered in my prepared remarks — we saw that patients who received placebo during the Clarity AD study at 18 months and were then switched to drug in the open label extension never truly caught up with what we refer to as the early stage, early start cohort. Even so, they preserved their difference relative to the early start group, which we believe reflects a disease-modifying effect... And then finally, when we overlay that with the ADNI data and the natural history data, we observe that patients who began even at 18 months actually sustained some degree of stabilization while on drug. So all of these lines of evidence lead us to the conclusion that continuing treatment at this point, to some degree, is going to matter. You're absolutely right that I think we are still working out what the correct frequency is and how long treatment should last. That is precisely what the maintenance substudy, which forms part of the phase II open label extension, is examining, and that's the data we are collecting. But we believe drug will need to be continued for a certain period of time, and patients will need to be monitored.
Christopher Viehbacher
executiveBroadly speaking, I'd put it this way: I've heard a lot of neurologists remark, "We used to view Alzheimer's disease as a four to eight-year illness, mostly starting once symptoms appear." Given what we understand today, many of them now say, "We're framing this across 25-year terms." It's known that plaques build up in patients well before symptoms show. And as Priya mentioned a moment ago, even once plaques are cleared, continuing treatment appears to offer some benefit. Thinking about this from a commercial angle, first, we have the AHEAD study, which has launched and is examining pre-symptomatic patients; it also underscores how much blood-based biomarkers matter, since that's the sole route by which we'll be able to detect and diagnose, or at minimum triage, patients initially at an earlier stage. And naturally, that's where the subQ formulation also becomes significant. Because if we're contemplating people remaining on drug longer — and I'm certainly not proposing 25 years, but this could be a considerably longer stretch, certainly than the 18 months — then the convenience of the subQ formulation matters even more. So we learn something every day. I mean, I think we witnessed that at CTAD, where we increasingly grasp how important early treatment is. We're seeing how important staying on treatment is, or the benefit of potentially staying on it; so that carries all sorts of commercial implications, along with how we run more studies and develop different formulations. It's actually quite exciting.
Chuck Triano
executiveThank you, Chris.
Chuck Triano
executivePlease, let's go on to the following question.
Umer Raffat
analystHi, guys. Appreciate you making room for me. I'd like to zero in on lecanemab subQ; and Priya, I believe you brought up two points. First, there's a subQ maintenance filing, which is a separate matter, potentially in 2025. Could you confirm whether the dose is lower, and whether it's a single shot rather than two? And second, regarding the FDA interactions on subQ that you brought up, are those a follow-up to a trial design for subQ that was agreed upon previously, or do you feel you need clarity on whether plaque reduction by itself will be enough for filing? Thank you.
Priya Singhal
executiveThanks, Umer. Starting with maintenance and subQ — that’s really a much later potential evaluation and filing, so I won’t be able to go into more detail specifically about dose, because the first thing we need is to evaluate IV maintenance, and that’s genuinely the next milestone on the docket. Then, returning to your other question about the purpose of the FDA regulatory meeting: maybe just to step back — Eisai held a number of meetings with FDA before launching the subcutaneous open label extension substudy that I mentioned, and from Clarity AD. What we know for certain is that demonstrating bioequivalence on PK is required, and beyond that, comparability in plaque reduction must also be shown. From the six-month data we recently presented—and that Eisai discussed at CTAD—we think we've met that bar. That covers the first piece. Then for the second piece: given that we're seeing an 11% rise in overall AUC, meaning area under the curve exposure, along with 14% greater plaque removal at the six-month mark, the question becomes whether that translates into a different dose. That's really something we'd need to talk through, and it would require conversations with the FDA, so I can't say much more about it; the key point, though, is that the aim was demonstrating bioequivalence, and we believe we've done that.
Chuck Triano
executiveThanks, Priya.
Chuck Triano
executiveNext question.
Michael Yee
analystThank you. Good morning, everyone. I'd like to return to something regarding the AHEAD 3 to 45 study. From what I understand, your partner said not long ago that an interim analysis could be conducted based on 400 patients in biomarkers. I realize the study has been enrolling for some time, though perhaps it is only now gaining momentum. Could you speak a bit about how that study is progressing, how you view it, and where things stand with patients being enrolled? Many thanks.
Priya Singhal
executiveCertainly. What I can share is that this represents a highly significant component. The AHEAD 3 to 45 study forms a very important piece of the broader development plan for LEQEMBI as an anti-amyloid agent. The reason is that, and I think Chris brought this up too a few minutes back, we understand that plaque accumulates, amyloid plaque accumulates over many years, and then there is a kind of transition at which tau tangles begin to emerge, followed by the onset of symptoms. So over the past several years, a great deal of work has gone into clinical staging and related areas, and we know that the anti-amyloid agents available now, such as LEQEMBI, which is really the sole agent holding traditional approval, target mild cognitive impairment, patients with mild cognitive impairment along with mild dementia. Yet those patients already show symptoms and possibly a tau burden. What AHEAD 3 to 45 aims to do is examine varying levels of amyloid plaque in patients without symptoms and determine whether adding an anti-amyloid agent such as Leqembi can change how the disease progresses. That is truly the central objective of a study like AHEAD 3 to 45; it is a very large study. As you might expect, finding the patients is difficult, but we are quite pleased with how the study is advancing. And as Eisai noted very recently, there is the possibility of conducting an interim analysis and considering whether additional regulatory pathways might be available using interim data. But we have not said anything further than that. Such options remain possibilities, though I believe it will hinge on how successful recruitment is and what the aims for eventual patient access turn out to be. Thank you.
Chuck Triano
executiveGreat. Let's go to our next question, please.
Terence Flynn
analystGreat, and thanks for taking my question. I've got just a two-part one for you. I was just wondering whether you could give us any additional detail on how broad the prescribing of LEQEMBI is. I know you provided us with that 800 patient figure, but it would be helpful to see how many centers that spans. And then, I know you made a few remarks about, you know, some headway on MAC coverage. Any further specifics on the timelines for when we might see wider coverage at the MAC level? I know a couple of MACs are already covering it, but anything you could add there would be helpful. Thank you.
Christopher Viehbacher
executiveYeah, Terence, I really don't have anything new to share regarding the MACs. As I recall, there are around 12 of them, and each one sits at a different stage. My sense is that by the time things move further along — once most of them have reached that point — the assumption is it takes roughly 60 to 90 days to work through, so that puts us near the end of the year. On coverage, one of the most interesting aspects is genuinely how varied the situations we encounter are. I speak with certain physicians at a few major medical centers, and they already have the protocol as well as the treatments. Patients are now being scheduled routinely. Still, I've spoken with several large medical centers that you'd assume already have this figured out, yet they continue to work through the protocols—specifically, which patient profile is appropriate for inclusion. This calls for a team-based approach, so coordination among staff is essential. With certain IDNs, all the pieces are in place, but they need to link up internally across their MRI centers and infusion centers. So providing a sweeping generalization is somewhat difficult. I'd say that each day we're identifying more and more patients, obviously, who are making it through the course of treatment. We're monitoring a range of upstream indicators, since revenue really is a lagging measure. You know, even from the point when we begin reviewing registry results, it takes roughly four to six weeks before we actually observe those patients starting on the drug; but, you know, some of those timelines shift constantly. So this is a fairly fluid process. You know, it's just, you know, things change daily. And so that's where, you know, at some point we build enough momentum, and we clear enough of these barriers. You know, one of the biggest remains getting an appointment with a neurologist. That’s the context for how we’re evaluating what blood-based biomarkers—which are already available—can accomplish. Clearly not as a substitute for PET scans or MRIs, but might they serve a triage role, so that those who actually reach a neurology clinic are already eligible? A lot of thinking is therefore taking place in real time as we gain insight from this experience. Once more, this is genuinely a case with few strong analogs. Some people, you know, attempt to point to the CAR-T approach, and although that too involves a product within a process, the volumes and scale in this situation differ considerably. We clearly aren’t close to the complexity of a CAR-T strategy, so there aren’t really comparable approaches for us to follow—meaning we’re picking things up as we proceed. Still, as I mentioned, progress happens daily, and every signal so far is positive; what’s needed now is simply sufficient scale across all the sites that have their care networks and care pathways established.
Chuck Triano
executiveThank you, Chris.
Chuck Triano
executiveCould we move on to the following question, please?
Paul Matias
analystHi there, I appreciate you fielding my question. Chris, you brought up a moment ago that a neurologist appointment had been secured, and earlier on this call you noted the registry requirement isn't quite the hurdle it was made out to be. What I'd like to probe is the remaining infrastructure elements around LEQEMBI — the IVs, PET scans, and MRIs. Could you rank those parts of the equation from hardest to easiest for centers to work through? And by roughly next summer, what do you picture this overall infrastructure network looking like? Many thanks.
Christopher Viehbacher
executiveSure — the picture varies somewhat from place to place. The scenario isn’t identical at each center, though based on current knowledge I’d say there’s obviously a need right now to secure a neurologist appointment. The fact is, not many patients were already in neurology practices—they’re usually in PCP practices—and neurologists were already busy. So we now have a substantial number of patients to move through those neurology practices. Many of them are recognizing, “I may need to add staff here. Do I have enough business to justify adding staff?” It may not involve neurologists specifically, but possibly nurse practitioners or other clinicians who can handle portions of the care pathway. For certain of these groups, the work involves moving through their internal governance procedures and figuring out which patients are appropriate at this point in time. There is obviously a great deal of caution surrounding ARIA. My own personal view is that neurologists will grow more familiar with understanding ARIA as time goes on. Does a distinction exist between the asymptomatic and the symptomatic? They will gain considerably more experience, but they are focused on making sure that the patients who proceed are attempting to achieve the lowest possible risk of ARIA. From what I can tell, infusion center capacity doesn't appear to be a major concern at most centers. As for PET scans, there seem to be sufficient numbers available based on what we know; the real question has been, you know, how do I secure reimbursement for it? Is it only a single one? And it was mostly the uncertainty surrounding that. So I believe having clarity on this will simply remove one of the, you know, discussion factors and some time from the process; and, you know, at every stage, you know, if you send a patient out for the PET scan, the results have to come back. A PET scan reader has interpreted it, you know, but at times a physician would prefer someone within that practice to review it. So, you know, it's simply about connecting and directing the patient to all these various points, even inside an integrated delivery network. I don't believe any single factor is at play here, though I would add that if we could enhance how patients get triaged before they even reach the neurologist, that would certainly be beneficial. But I think it's… It truly is the case that this is transforming how many clinics practice, and all of them are having to navigate that. And these are, naturally, extremely busy individuals. They have other demands, so finding the time to actually handle all of this is understandably difficult. So I think it’s entirely natural, and to be expected, that progress here is slow. Yet again, you know, you do see some moving very quickly, and that definitely gives me confidence that others will work this out as well.
Chuck Triano
executiveThank you, Chris. And Allie, could we—
Phil Nadeau
analystMorning. Appreciate you squeezing me in. I'd like to ask about the European Medicines Agency review of Skyclarys. Can you share a little more on where that review currently stands? Has an oral explanation been required at any point? And more broadly, how confident is Biogen that a favorable CHMP opinion will be obtained during the first half of 2024? Thank you.
Christopher Viehbacher
executivePri, would you like to handle that question?
Priya Singhal
executiveAbsolutely. Appreciate the question. Taking a broader view, throughout diligence we went through regulatory correspondence, and we had some degree of familiarity with those topics. After the deal closed, we've had additional regulatory interactions, and as Chris said, nothing has shifted our thinking. We still anticipate an outcome in early 2024, so that continues as planned. As for whether an oral explanation will occur, that's genuinely not something we comment on since it's under review, and that falls within the review details. Hopefully that answers it. Thank you.
Chuck Triano
executiveAppreciate it, Pri — that brings us to the end of today's call. Thank you all for being with us. The IR team will, of course, be around afterward for any remaining follow-up questions.
Operator
operatorThanks. That brings us to the end of today's conference, ladies and gentlemen. We appreciate you joining us. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.